December 1, 2022 – Renal & Urology News (By: Natasha Persaud) Veterans with cardiovascular disease or diabetes have slightly longer survival when treated with enzalutamide vs abiraterone for metastatic castration-resistant prostate cancer (mCRPC), a new study finds. In a retrospective study of 5822 veterans treated for mCRPC during 2014-2017, 43% initially received enzalutamide, an androgen…
Read MoreDr. Raju Thomas wins the Karl Storz Lifetime Achievement Award from the Endourological Society for 2022. This award is only made to those few urologists who have made significant and lasting contributions to the field of Endourology and to our Society.
Read More